HRP20050184B1 - Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima - Google Patents

Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima

Info

Publication number
HRP20050184B1
HRP20050184B1 HRP20050184AA HRP20050184A HRP20050184B1 HR P20050184 B1 HRP20050184 B1 HR P20050184B1 HR P20050184A A HRP20050184A A HR P20050184AA HR P20050184 A HRP20050184 A HR P20050184A HR P20050184 B1 HRP20050184 B1 HR P20050184B1
Authority
HR
Croatia
Prior art keywords
combination
alkylphospholine
tumor drugs
alkyl phosphocholines
phosphocholines
Prior art date
Application number
HRP20050184AA
Other languages
English (en)
Croatian (hr)
Inventor
Jürgen Engel
Günther Eckhard
Herbert Sindermann
Original Assignee
Æterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Æterna Zentaris Gmbh filed Critical Æterna Zentaris Gmbh
Publication of HRP20050184A2 publication Critical patent/HRP20050184A2/hr
Publication of HRP20050184B1 publication Critical patent/HRP20050184B1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20050184AA 2002-07-30 2003-07-29 Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima HRP20050184B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39961502P 2002-07-30 2002-07-30
PCT/EP2003/008346 WO2004012744A1 (de) 2002-07-30 2003-07-29 Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten

Publications (2)

Publication Number Publication Date
HRP20050184A2 HRP20050184A2 (en) 2005-04-30
HRP20050184B1 true HRP20050184B1 (hr) 2014-04-11

Family

ID=31495746

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050184AA HRP20050184B1 (hr) 2002-07-30 2003-07-29 Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima

Country Status (26)

Country Link
US (3) US8389497B2 (enExample)
EP (2) EP1545553B1 (enExample)
JP (1) JP2005535688A (enExample)
KR (3) KR101066804B1 (enExample)
CN (1) CN1302780C (enExample)
AR (1) AR040717A1 (enExample)
AT (1) ATE516036T1 (enExample)
AU (2) AU2003253350B2 (enExample)
BR (1) BR0313048A (enExample)
CA (1) CA2493023C (enExample)
CY (1) CY1111902T1 (enExample)
DK (1) DK1545553T3 (enExample)
ES (1) ES2369535T3 (enExample)
HR (1) HRP20050184B1 (enExample)
IL (1) IL166329A (enExample)
MX (1) MXPA05001203A (enExample)
NO (1) NO335196B1 (enExample)
NZ (1) NZ538428A (enExample)
PL (1) PL375493A1 (enExample)
PT (1) PT1545553E (enExample)
RU (1) RU2005105693A (enExample)
SI (1) SI1545553T1 (enExample)
TW (1) TWI332007B (enExample)
UA (1) UA82322C2 (enExample)
WO (1) WO2004012744A1 (enExample)
ZA (1) ZA200500453B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
TWI332007B (en) 2002-07-30 2010-10-21 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals
DE10324911B4 (de) 2003-05-30 2005-08-18 Siemens Ag Röntgenvorrichtung mit partiellem digitalem Detektor und Verfahren zum Betrieb einer solchen
WO2006081452A2 (en) * 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
WO2009018233A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
JP5232009B2 (ja) * 2005-12-19 2013-07-10 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された細胞毒性を有するアルキルリン脂質誘導体並びにそれらの使用
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
CN101340918B (zh) * 2005-12-19 2012-10-03 阿特纳赞塔里斯有限公司 具有降低细胞毒性的新烷基磷脂衍生物及其用途
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
MX2011006167A (es) * 2008-12-11 2011-07-28 Abraxis Bioscience Llc Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion.
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033917A1 (de) * 1998-12-04 2000-06-15 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten
WO2002066019A2 (en) * 2001-02-19 2002-08-29 Novartis Ag Cancer treatment
WO2003055522A1 (en) * 2002-01-02 2003-07-10 Pharmacia Italia Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
WO2005000318A2 (en) * 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59205998D1 (de) * 1991-07-04 1996-05-23 Asta Medica Ag Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
US5942639A (en) * 1991-07-04 1999-08-24 Asta Medica Aktiengesellschaft Process for the preparation of alkylphosphocholines and the production thereof in pure form
US6172050B1 (en) * 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
JP3079993B2 (ja) * 1996-03-27 2000-08-21 日本電気株式会社 真空マイクロデバイスおよびその製造方法
DE19650778C2 (de) * 1996-12-06 2001-01-04 Asta Medica Ag Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie
PL189654B1 (pl) * 1998-01-22 2005-09-30 Zentaris Gmbh Zastosowanie miltefosyny do wytwarzania leków
CA2356736A1 (en) * 1998-12-21 2000-06-29 Inkeysa. S.A. Use of etherlysophospholipids as antiinflammatory agents
PL365285A1 (en) * 2001-03-23 2004-12-27 Shire Biochem Inc. Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
WO2003005522A1 (es) 2001-07-04 2003-01-16 Acuna Arturo Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica.
TWI332007B (en) 2002-07-30 2010-10-21 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals
WO2006081452A2 (en) 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
CN101340918B (zh) * 2005-12-19 2012-10-03 阿特纳赞塔里斯有限公司 具有降低细胞毒性的新烷基磷脂衍生物及其用途
MX2011011596A (es) * 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033917A1 (de) * 1998-12-04 2000-06-15 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten
WO2002066019A2 (en) * 2001-02-19 2002-08-29 Novartis Ag Cancer treatment
WO2003055522A1 (en) * 2002-01-02 2003-07-10 Pharmacia Italia Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
WO2005000318A2 (en) * 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERKOVIC D ET AL: "The influence of 1-beta-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells." LEUKEMIA: OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K. ENGLAND DEC 1997, Bd. 11, Nr. 12, Dezember 1997 (1997-12),2079-2086 str. *
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; Februar 1991 (1991-02) SHOJI M ET AL: "Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells." Database accession no. NLM2051897 XP002256716 & LIPIDS. UNITED STATES FEB 1991, Bd. 26, Nr. 2, Februar 1991 (1991-02), 145-149 str. *
GEORGIEVA MILKA C ET AL: "Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells." CANCER LETTERS. IRELAND 28 AUG 2002, Bd. 182, Nr. 2, 28. August 2002 (2002-08-28), 163-174 str. *
HILGARD P ET AL: "Heterocyclic alkylphospholipids with an improved therapeutic range." ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. UNITED STATES 1996, Bd. 416, 1996,157-164 str. *
SPRUSS T ET AL: "ANTITUMOUR ACTIVITY OF MILTEFOSINE ALONE AND AFTER COMBINATION WITHPLATINUM COMPLEXES ON MXT MOUSE MAMMARY CARCINOMA MODELS" JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, Bd. 119, Nr. 3, 1993,142-149 str. *
STEKAR J ET AL: "Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide." EUROPEAN JOURNAL OF CANCER (OXFORD, ENGLAND: 1990) ENGLAND 1995, Bd. 31A, Nr. 3, 1995, 372-374 str. *

Also Published As

Publication number Publication date
HRP20050184A2 (en) 2005-04-30
PL375493A1 (en) 2005-11-28
DK1545553T3 (da) 2011-09-12
US8389497B2 (en) 2013-03-05
JP2005535688A (ja) 2005-11-24
IL166329A0 (en) 2006-01-15
NO20051040L (no) 2005-02-25
US8507710B2 (en) 2013-08-13
IL166329A (en) 2012-08-30
US20100190738A1 (en) 2010-07-29
KR20130016413A (ko) 2013-02-14
TWI332007B (en) 2010-10-21
CY1111902T1 (el) 2015-11-04
EP1545553A1 (de) 2005-06-29
US20100189784A1 (en) 2010-07-29
CN1302780C (zh) 2007-03-07
SI1545553T1 (sl) 2011-09-30
KR20110102485A (ko) 2011-09-16
US8551977B2 (en) 2013-10-08
RU2005105693A (ru) 2005-07-10
KR101066804B1 (ko) 2011-09-22
AU2003253350B2 (en) 2008-06-26
CA2493023A1 (en) 2004-02-12
ATE516036T1 (de) 2011-07-15
NO335196B1 (no) 2014-10-20
PT1545553E (pt) 2011-09-12
WO2004012744A1 (de) 2004-02-12
ZA200500453B (en) 2005-08-31
KR20050026028A (ko) 2005-03-14
EP2301551A1 (de) 2011-03-30
TW200404073A (en) 2004-03-16
MXPA05001203A (es) 2005-06-08
BR0313048A (pt) 2005-06-14
CN1671397A (zh) 2005-09-21
CA2493023C (en) 2012-01-31
NZ538428A (en) 2006-09-29
AR040717A1 (es) 2005-04-20
EP1545553B1 (de) 2011-07-13
AU2008203060B2 (en) 2011-04-21
ES2369535T3 (es) 2011-12-01
AU2003253350A1 (en) 2004-02-23
HK1080751A1 (en) 2006-05-04
US20040097470A1 (en) 2004-05-20
AU2008203060A1 (en) 2008-07-31
UA82322C2 (uk) 2008-04-10

Similar Documents

Publication Publication Date Title
MEP36208A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
CY1111700T1 (el) Αναστολεις των νουκλεοζιτικων φωσφορυλασων και νουκλεοζιδασων
YU21401A (sh) Tetrahidropiridoetri
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
CR7182A (es) Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
HRP20050184B1 (hr) Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima
ATE552259T1 (de) Inhibitoren von nukleosidphosphorylasen und - nukleosidasen
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
NO20042035L (no) Forbedret anvendelse av antitumorforbindelse i kreftterapi
WO2003106384A3 (en) Novel boronic chalcone derivatives and uses thereof
EP1546182A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSING AND TREATING TUMORS
ATE407937T1 (de) Rutheniumkomplexe mit antikrebswirkung
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
MXPA05008817A (es) Derivados de esteres lipidos de nucleotidos.
FR2877667B1 (fr) Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
ATE336244T1 (de) Metallorganisches antitumormittel
MXPA05008293A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE502004008294D1 (de) Neue makrocyclen zur behandlung von krebserkrankungen
BR0208322A (pt) Derivados de açúcar citotóxixo seletivo da topoisomerase i de indolopirrolocarbazóis

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: ZENTARIS GMBH, DE

PNAN Change of the applicant name, address/residence

Owner name: ÆTERNA ZENTARIS GMBH, DE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160714

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20170729